Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) | |
US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) | |
US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 25, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: June, 2027
Market Authorisation Date: 25 June, 2018
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic